DK1572946T3 - Terapeutisk humant monoklonalt anti-IL-1R1-antistof - Google Patents
Terapeutisk humant monoklonalt anti-IL-1R1-antistofInfo
- Publication number
- DK1572946T3 DK1572946T3 DK03752058.2T DK03752058T DK1572946T3 DK 1572946 T3 DK1572946 T3 DK 1572946T3 DK 03752058 T DK03752058 T DK 03752058T DK 1572946 T3 DK1572946 T3 DK 1572946T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- human monoclonal
- monoclonal anti
- therapeutic human
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40871902P | 2002-09-06 | 2002-09-06 | |
PCT/US2003/027978 WO2004022718A2 (en) | 2002-09-06 | 2003-09-05 | Therapeutic human anti-il-1r1 monoclonal antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1572946T3 true DK1572946T3 (da) | 2012-07-02 |
Family
ID=31978664
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03752058.2T DK1572946T3 (da) | 2002-09-06 | 2003-09-05 | Terapeutisk humant monoklonalt anti-IL-1R1-antistof |
DK10003365.3T DK2213685T3 (da) | 2002-09-06 | 2003-09-05 | Terapeutisk anti-IL-1R1-monoklonalt antistof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10003365.3T DK2213685T3 (da) | 2002-09-06 | 2003-09-05 | Terapeutisk anti-IL-1R1-monoklonalt antistof |
Country Status (29)
Country | Link |
---|---|
US (5) | US7438910B2 (da) |
EP (4) | EP1572946B1 (da) |
JP (4) | JP4317817B2 (da) |
KR (2) | KR101317045B1 (da) |
CN (3) | CN101628939B (da) |
AR (1) | AR041173A1 (da) |
AT (1) | ATE549033T1 (da) |
AU (2) | AU2003270370A1 (da) |
BR (1) | BRPI0314038B8 (da) |
CA (2) | CA2497884C (da) |
CY (1) | CY1112858T1 (da) |
DK (2) | DK1572946T3 (da) |
EA (2) | EA033750B1 (da) |
ES (3) | ES2565189T3 (da) |
HK (3) | HK1084688A1 (da) |
IL (4) | IL167073A (da) |
ME (2) | MEP32508A (da) |
MX (1) | MXPA05002514A (da) |
NO (2) | NO337245B1 (da) |
NZ (5) | NZ593428A (da) |
PH (1) | PH12012501089A1 (da) |
PL (1) | PL377091A1 (da) |
PT (1) | PT1572946E (da) |
RS (2) | RS52889B (da) |
SG (2) | SG196688A1 (da) |
SI (1) | SI1572946T1 (da) |
TW (3) | TWI289668B (da) |
WO (1) | WO2004022718A2 (da) |
ZA (1) | ZA200501792B (da) |
Families Citing this family (200)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050043234A1 (en) | 1996-10-16 | 2005-02-24 | Deisher Theresa A. | Novel FGF homologs |
WO2000029581A1 (en) | 1998-11-13 | 2000-05-25 | Immunex Corporation | Human tslp dna and polypeptides |
DK1399484T3 (da) * | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
WO2003032898A2 (en) | 2001-07-23 | 2003-04-24 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
NZ593428A (en) | 2002-09-06 | 2013-01-25 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
EP1551426B1 (en) | 2002-10-07 | 2014-06-25 | ZymoGenetics, Inc. | Methods of administering fgf18 |
GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
EP2902491A1 (en) | 2003-03-19 | 2015-08-05 | Biogen MA Inc. | NOGO receptor binding protein |
WO2004100987A2 (en) * | 2003-05-06 | 2004-11-25 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat neointimal hyperplasia |
MXPA05014152A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
SI2805728T1 (sl) * | 2003-12-23 | 2020-07-31 | Genentech, Inc. | Nova protitelesa proti il 13 in uporabe le-teh |
DK1729810T3 (da) | 2004-04-02 | 2018-12-03 | Swedish Orphan Biovitrum Ab Publ | Fremgangsmåde til reduktion af aggregering af il-1ra |
EP1750746A1 (en) * | 2004-06-04 | 2007-02-14 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat autoinflammatory disease |
ES2395094T3 (es) | 2004-06-24 | 2013-02-08 | Biogen Idec Ma Inc. | Tratamiento de afecciones que implican la desmielinización |
US20060009389A1 (en) | 2004-07-06 | 2006-01-12 | Moore Emma E | Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use |
WO2006023791A2 (en) * | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
BRPI0518622A2 (pt) * | 2004-12-02 | 2008-12-02 | Domantis Ltd | usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
WO2006084145A2 (en) * | 2005-02-02 | 2006-08-10 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to reduce c-reactive protein |
EA012801B1 (ru) | 2005-06-14 | 2009-12-30 | Эмджен Инк. | Самобуферирующиеся композиции белков |
DK2314623T3 (da) | 2005-06-21 | 2012-09-17 | Xoma Technology Ltd | Il-1 beta-bindende antistoffer og fragmenter deraf |
MX2008000253A (es) | 2005-07-08 | 2008-04-02 | Biogen Idec Inc | Anticuerpos de sp35 y usos de los mismos. |
AU2006274698B2 (en) * | 2005-08-02 | 2011-06-09 | Xbiotech, Inc. | Diagnosis, treatment, and prevention of vascular disorders using IL-1a autoantibodies |
WO2007042524A2 (en) * | 2005-10-14 | 2007-04-19 | Novo Nordisk A/S | Treating diabetes using inhibitors of il-1 |
BRPI0619225A2 (pt) * | 2005-12-01 | 2017-11-07 | Domantis Ltd | monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória |
US20080311111A1 (en) * | 2005-12-01 | 2008-12-18 | Drew Philip D | Competitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1 |
US20080107597A1 (en) * | 2006-01-12 | 2008-05-08 | Anaptys Biosciences, Inc. | Isolation of antibodies that cross-react and neutralize rankl originating from multiple species |
US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
CN107158376A (zh) * | 2006-05-22 | 2017-09-15 | 埃克斯生物科技公司 | 使用抗IL‑1α抗体治疗癌症 |
RU2554747C9 (ru) | 2006-12-20 | 2015-10-20 | Ксома (Сша) Ллс | Способы лечения il-1бета-зависимых заболеваний |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
WO2008088594A2 (en) * | 2007-01-12 | 2008-07-24 | Anaptysbio, Inc. | Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species |
CA2688433A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
UA102993C2 (ru) * | 2007-06-06 | 2013-09-10 | Домантис Лимитед | Анти-vegf единичный вариабельный домен иммуноглобулина |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
US20110097318A1 (en) * | 2007-08-31 | 2011-04-28 | Amgen Inc. | Solid-State Protein Formulation |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
MX2010002683A (es) | 2007-09-14 | 2010-03-26 | Amgen Inc | Poblaciones de anticuerpos homogeneos. |
US8431352B2 (en) | 2007-09-27 | 2013-04-30 | Virus Ikagaku Kenkyusho Inc. | Diagnosis of mood disorders by detecting latent infection with human herpesvirus-6 |
ES2750254T3 (es) | 2007-09-27 | 2020-03-25 | Amgen Inc | Formulaciones farmacéuticas |
ES2962777T3 (es) | 2007-11-15 | 2024-03-21 | Amgen Inc | Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral |
ES2527326T3 (es) | 2007-12-20 | 2015-01-22 | Xoma (Us) Llc | Métodos para el tratamiento de la gota |
WO2010005570A2 (en) | 2008-07-09 | 2010-01-14 | Biogen Idec Ma Inc. | Compositions comprising antibodies to lingo or fragments thereof |
JP2012502058A (ja) | 2008-09-05 | 2012-01-26 | ゾーマ テクノロジー リミテッド | β細胞機能の改善のための方法 |
JP5976319B2 (ja) * | 2008-09-12 | 2016-08-23 | エックスバイオテク,インコーポレイテッドXbiotech,Inc. | 病原性単球の標的化 |
US8298533B2 (en) * | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
JP5717030B2 (ja) | 2009-02-24 | 2015-05-13 | 学校法人金沢医科大学 | 有核赤血球の脱核方法及び脱核誘導剤 |
US20120064543A1 (en) * | 2009-03-02 | 2012-03-15 | Virus Ikagaku Kenkyusho Inc. | Method for detecting substance in biological sample |
CN102449483A (zh) * | 2009-03-31 | 2012-05-09 | 日本烟草产业株式会社 | 对生物学样品中的sith-1抗体进行检测的方法 |
ES2376931B1 (es) * | 2009-04-02 | 2013-06-25 | Universidad Del Pais Vasco | Composiciones farmacéuticas para el tratamiento de la metástasis. |
US9662271B2 (en) | 2009-10-23 | 2017-05-30 | Amgen Inc. | Vial adapter and system |
US20130149312A1 (en) * | 2010-04-16 | 2013-06-13 | Mcmaster University | Compositions and methods for treating copd exacerbation |
KR20130065662A (ko) | 2010-05-07 | 2013-06-19 | 조마 테크놀로지 리미티드 | ⅠL-1β 관련 병태의 치료 방법 |
MX2012014180A (es) | 2010-06-07 | 2013-05-06 | Amgen Inc | Dispositivo de administracion de farmacos. |
KR20130098279A (ko) | 2010-06-18 | 2013-09-04 | 엑스바이오테크, 인크. | 관절염 치료 |
US8357692B2 (en) | 2010-06-20 | 2013-01-22 | Washington University | Methods of treatment of bone degenerative diseases |
MX2013002208A (es) | 2010-08-23 | 2013-05-30 | Amgen Inc | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. |
EP3075394B1 (en) | 2010-08-23 | 2018-11-28 | XBiotech, Inc | Treatment for neoplastic diseases |
EP2663330B1 (en) | 2011-01-10 | 2019-03-06 | NovImmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
US8889130B2 (en) * | 2011-02-08 | 2014-11-18 | Abbvie Inc. | Treatment of osteoarthritis and pain |
MX341790B (es) | 2011-03-31 | 2016-09-02 | Amgen Inc | Adaptador de viales y sistema. |
US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
WO2012138776A1 (en) | 2011-04-05 | 2012-10-11 | Amgen Inc. | Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes |
US20140308294A1 (en) * | 2011-04-15 | 2014-10-16 | Merck Patent Gmbh | Anti-IL-1R1 Inhibitors For Use in Cancer |
EP3498323B1 (en) | 2011-04-20 | 2022-07-13 | Amgen Inc. | Autoinjector apparatus |
WO2013007763A1 (en) | 2011-07-12 | 2013-01-17 | Universität Zürich | MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE |
US9809649B2 (en) | 2011-09-23 | 2017-11-07 | Xbiotech, Inc. | Cachexia treatment |
DE102011083595A1 (de) * | 2011-09-28 | 2013-03-28 | Bayer Pharma AG | Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose |
CA3175560A1 (en) | 2011-10-14 | 2013-04-18 | Amgen Inc. | Injector and method of assembly |
WO2013096516A1 (en) | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Methods for treating acne |
WO2013123444A1 (en) | 2012-02-17 | 2013-08-22 | Amgen Inc. | Sulfonyl compounds that interact with glucokinase regulatory protein |
CA2866341A1 (en) * | 2012-03-19 | 2013-09-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment or the prevention of aneurysm |
EP2849787A4 (en) | 2012-05-14 | 2016-06-15 | Biogen Ma Inc | LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISORDERS INVOLVING ENGINE NEURONS |
WO2013173382A1 (en) | 2012-05-15 | 2013-11-21 | Amgen Inc. | Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein |
AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
ES2951440T3 (es) | 2012-11-21 | 2023-10-20 | Amgen Inc | Dispositivo de administración de fármacos |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014107566A1 (en) | 2013-01-04 | 2014-07-10 | Massachusetts Institute Of Technology | Surface binding of nanoparticle based drug delivery to tissue |
US10492990B2 (en) | 2013-03-15 | 2019-12-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
CA2904725C (en) | 2013-03-15 | 2022-04-12 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
EP2976117B1 (en) | 2013-03-22 | 2020-12-30 | Amgen Inc. | Injector and method of assembly |
BR112016003665B1 (pt) * | 2013-08-30 | 2024-01-09 | Immunogen, Inc | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a um epítopo do receptor de folato 1, polinucleotídeo, vetor,célula hospedeira procariótica ou de levedura, composição, seus usos e métodos in vitro para detecção da expressão do receptor de folato 1 e identificação de um câncer |
AU2014318017B2 (en) | 2013-09-05 | 2020-02-06 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
CA2920894C (en) | 2013-10-24 | 2023-03-14 | Amgen Inc. | Injector and method of assembly |
CA3168888A1 (en) | 2013-10-24 | 2015-04-30 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
GB201400997D0 (en) * | 2014-01-21 | 2014-03-05 | Vib Vzw | Targeting of interleukin-1 and -18 in treatment of septic shock |
JP6640113B2 (ja) | 2014-05-07 | 2020-02-05 | アムジエン・インコーポレーテツド | 衝撃低減要素を有する自動注入器 |
EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
SG11201609970VA (en) | 2014-06-03 | 2016-12-29 | Amgen Inc | Systems and methods for remotely processing data collected by a drug delivery device |
TR201900776T4 (tr) * | 2014-06-04 | 2019-02-21 | Amgen Inc | Memeli hücre kültürlerinin hasadına ilişkin yöntem. |
CN104004061B (zh) * | 2014-06-23 | 2016-03-02 | 南通普悦生物医药有限公司 | 白介素-33抑制剂多肽及其应用 |
CN104031128B (zh) * | 2014-06-23 | 2016-03-30 | 浙江元太生物科技有限公司 | 一种白介素-33抑制剂多肽及其应用 |
CN104004059B (zh) * | 2014-06-23 | 2016-03-30 | 周越 | 一种关于白介素-33抑制剂多肽及其应用 |
EP3943135A3 (en) | 2014-10-14 | 2022-06-29 | Amgen Inc. | Drug injection device with visual and audible indicators |
ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
JP6716566B2 (ja) | 2014-12-19 | 2020-07-01 | アムジエン・インコーポレーテツド | 近接センサ付き薬物送達装置 |
EP3242893A1 (en) | 2015-01-08 | 2017-11-15 | Biogen MA Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
ES2748750T3 (es) | 2015-02-17 | 2020-03-17 | Amgen Inc | Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación |
WO2016138434A1 (en) | 2015-02-27 | 2016-09-01 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
CN115505042A (zh) | 2015-06-26 | 2022-12-23 | 赛诺菲生物技术公司 | 单克隆抗il-1racp抗体 |
PT3334747T (pt) | 2015-08-13 | 2023-12-12 | Amgen Inc | Formulação de gonadotrofina líquida estável |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
EP3384294B1 (en) | 2015-12-04 | 2021-10-13 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
US10539578B2 (en) | 2015-12-28 | 2020-01-21 | Japan Tobacco Inc. | Method for diagnosing, treating, or preventing mood disorders |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
WO2017160799A1 (en) | 2016-03-15 | 2017-09-21 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
AU2017263558B2 (en) | 2016-05-13 | 2022-12-22 | Amgen Inc. | Vial sleeve assembly |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
CN110290807B (zh) | 2016-12-03 | 2024-06-14 | 朱诺治疗学股份有限公司 | 确定car-t细胞给药的方法 |
KR101868701B1 (ko) | 2016-12-05 | 2018-07-17 | 동의대학교 산학협력단 | 보리가루 및 상엽 추출물을 포함하는 면류의 제조방법 |
CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
EP3582813A4 (en) | 2017-02-16 | 2020-12-30 | XBiotech, Inc | TREATMENT OF SUPPURATIVE HIDRADENITIS |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
US11752258B2 (en) | 2017-02-17 | 2023-09-12 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
IL268478B2 (en) | 2017-03-07 | 2023-10-01 | Amgen Inc | Inserting a needle using super pressure |
IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
EP3596225A1 (en) | 2017-03-14 | 2020-01-22 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
US11957883B2 (en) | 2017-03-28 | 2024-04-16 | Amgen Inc. | Plunger rod and syringe assembly system and method |
UY37651A (es) | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
AU2018275891A1 (en) | 2017-06-02 | 2019-12-12 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
AU2018275894A1 (en) | 2017-06-02 | 2019-12-12 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
WO2018226565A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
EP3638697A4 (en) | 2017-06-12 | 2021-07-07 | Bluefin Biomedicine, Inc. | ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES |
MX2019015472A (es) | 2017-06-22 | 2020-02-19 | Amgen Inc | Reduccion del impacto/choque de la activacion del mecanismo. |
JP7475860B2 (ja) | 2017-06-23 | 2024-04-30 | アムジエン・インコーポレーテツド | スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス |
WO2019006427A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES |
EP3651832B1 (en) | 2017-07-14 | 2023-12-13 | Amgen Inc. | Needle insertion-retraction system having dual torsion spring system |
IL271173B2 (en) | 2017-07-21 | 2024-04-01 | Amgen Inc | Gas permeable sealing element for drug container and methods of assembly |
WO2019022951A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF |
WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF |
WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
US20210071258A1 (en) | 2017-09-01 | 2021-03-11 | Juno Therapeutics, Inc. | Gene expression and assessment of risk of developing toxicity following cell therapy |
ES2939292T3 (es) | 2017-10-04 | 2023-04-20 | Amgen Inc | Adaptador de flujo para dispositivo de administración de fármacos |
EP3691716B1 (en) | 2017-10-06 | 2023-11-29 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
IL273323B1 (en) | 2017-10-09 | 2024-06-01 | Amgen Inc | Drug delivery device with drive assembly and related assembly method |
WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
US11826480B2 (en) | 2017-11-03 | 2023-11-28 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
WO2019089178A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
US20200338271A1 (en) | 2017-11-06 | 2020-10-29 | Amgen Inc. | Fill-finish assemblies and related methods |
MA50557A (fr) | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
MA50904A (fr) | 2017-11-16 | 2020-09-23 | Amgen Inc | Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament |
MX2020005066A (es) | 2017-11-16 | 2020-08-20 | Amgen Inc | Autoinyector con deteccion de detencion y punto final. |
WO2019100111A1 (en) * | 2017-11-21 | 2019-05-31 | Monash University | Methods of treating and diagnosing conditions |
CN111989106A (zh) | 2017-12-01 | 2020-11-24 | 朱诺治疗学股份有限公司 | 基因工程化细胞的给药和调节方法 |
US20210046159A1 (en) | 2018-03-09 | 2021-02-18 | Ospedale San Raffaele S.R.L. | Il-1 antagonist and toxicity induced by cell therapy |
CN111954719A (zh) | 2018-03-26 | 2020-11-17 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
MX2021000749A (es) | 2018-07-24 | 2021-03-29 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
WO2020028009A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
EP3836954A1 (en) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
CA3106452A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
IL281469B1 (en) | 2018-09-28 | 2024-04-01 | Amgen Inc | Assembling a memory alloy ejector activation assembly for a drug delivery device |
WO2020072577A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
AR116607A1 (es) | 2018-10-05 | 2021-05-26 | Amgen Inc | Dispositivo de administración de fármacos con indicador de dosis |
EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
CN112689523A (zh) | 2018-10-15 | 2021-04-20 | 安进公司 | 用于药物递送装置的平台组装方法 |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
EP3873566A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
CA3113076A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
PT3886875T (pt) | 2018-11-30 | 2024-06-27 | Juno Therapeutics Inc | Métodos para tratamento utilizando terapia celular adotiva |
AU2019387494A1 (en) | 2018-11-30 | 2021-06-10 | Juno Therapeutics, Inc. | Methods for dosing and treatment of B cell malignancies in adoptive cell therapy |
CA3137360A1 (en) | 2019-04-24 | 2020-10-29 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
US20220233710A1 (en) * | 2019-05-20 | 2022-07-28 | Nantong Yichen Biopharma. Co. Ltd. | Bispecific molecule and preparation and use thereof |
EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
AU2020355251A1 (en) | 2019-09-26 | 2022-04-21 | Amgen Inc. | Methods of producing antibody compositions |
IL293393A (en) | 2019-12-06 | 2022-07-01 | Juno Therapeutics Inc | Cell therapy-related toxicity and response-related methods for the treatment of b-cell malignancies |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
WO2022056276A1 (en) * | 2020-09-11 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
CA3197930A1 (en) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
AU2022279223A1 (en) | 2021-05-21 | 2023-10-19 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
EP4352094A1 (en) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
CA3226176A1 (en) * | 2021-07-13 | 2023-01-19 | Serodus Aps | Il1ra derived peptides for treatment of diabetic nephropathy |
CN113484526A (zh) * | 2021-08-11 | 2021-10-08 | 上海迈晋生物医药科技有限公司 | 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法 |
CN118139643A (zh) * | 2021-09-03 | 2024-06-04 | 新石生物制药有限公司 | 与PD-L1、CD137和/或TGFβ的双特异性和三特异性结合蛋白及其用途 |
CA3233279A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
DE3206821C2 (de) | 1982-02-26 | 1984-02-02 | Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe | Verfahren zur Abtrennung von leichtem Zusatzgas bei Trenndüsenkaskaden |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
JPS6291197A (ja) | 1985-10-17 | 1987-04-25 | Dainippon Pharmaceut Co Ltd | 抗ヒトインタ−ロイキン1抗体,その製法及びその使用法 |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5359032A (en) | 1987-08-26 | 1994-10-25 | Biogen Inc. | Interkeukin-1 inhibitor |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
US5081228A (en) * | 1988-02-25 | 1992-01-14 | Immunex Corporation | Interleukin-1 receptors |
US6511665B1 (en) * | 1987-11-25 | 2003-01-28 | Immunex Corporation | Antibodies to interleukin-1 receptors |
US5319071A (en) | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US5296592A (en) * | 1987-11-25 | 1994-03-22 | Immunex Corporation | Process for purifying interleukin-1 receptors |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
DE68925935T2 (de) | 1988-10-01 | 1996-08-14 | Otsuka Pharma Co Ltd | Antikörper gegen Interleukin-1-beta |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ATE102631T1 (de) * | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
AU651955B2 (en) | 1989-11-29 | 1994-08-11 | Amgen, Inc. | Production of recombinant human interleukin-1 inhibitor |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
AU649245B2 (en) | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
WO1991017184A1 (en) | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
US5872095A (en) | 1990-05-01 | 1999-02-16 | Chiron Corporation | IL-1 receptor antagonists medicaments |
AU655766B2 (en) | 1990-05-01 | 1995-01-12 | Chiron Corporation | Interleukin-1 antagonist and uses thereof |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5840496A (en) | 1990-10-09 | 1998-11-24 | Chiron Corporation | Method for diagnosing endometrial cancer |
US5858355A (en) | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
CA2106079C (en) | 1991-03-15 | 2000-04-25 | Robert C. Thompson | Pegylation of polypeptides |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
CA2111348A1 (en) | 1991-06-14 | 1992-12-23 | John S. Logan | Production of human hemoglobin in transgenic pigs |
WO1993001227A1 (en) | 1991-07-08 | 1993-01-21 | University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
ES2191013T3 (es) | 1992-03-04 | 2003-09-01 | Cell Therapeutics Inc | Compuestos de xantina enantiomeros hidroxilados. |
JPH07509223A (ja) | 1992-04-30 | 1995-10-12 | アムジェン インコーポレイテッド | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
DE4219626A1 (de) | 1992-06-16 | 1993-12-23 | Wehling Peter Priv Doz Dr Med | Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen |
JPH0630788A (ja) | 1992-07-16 | 1994-02-08 | Otsuka Pharmaceut Co Ltd | ヒトインターロイキン−1に対する組換え抗体 |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
JP3626755B2 (ja) | 1992-09-17 | 2005-03-09 | アムジェン インコーポレイテッド | インターロイキン−1インヒビターの薬学的処方物 |
US5866576A (en) | 1992-12-16 | 1999-02-02 | Cell Therapeutics, Inc. | Epoxide-containing compounds |
EP0701563A4 (en) | 1993-03-08 | 1997-07-02 | Univ Pittsburgh | GENE TRANSFER FOR THE TREATMENT OF CONNECTIVE TISSUES IN A HOST MAMMAL |
JP3723206B2 (ja) | 1993-03-19 | 2005-12-07 | バクスイン・エス・アー | ムラミルペプチドとサイトカインとを組み合わせることを特徴とするヒトに用いる治療用組成物 |
US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US5843905A (en) | 1993-06-04 | 1998-12-01 | Vertex Pharmaceuticals, Incorporated | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors |
FR2706772A1 (en) | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5608035A (en) | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
US5817476A (en) | 1995-06-07 | 1998-10-06 | Genetics Institute, Inc. | Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins |
ATE352613T1 (de) | 1995-08-29 | 2007-02-15 | Kirin Brewery | Chimäres tier und methode zu dessen herstellung |
JPH11511463A (ja) | 1995-08-31 | 1999-10-05 | スミスクライン・ビーチャム・コーポレイション | インターロイキン変換酵素およびアポプトーシス |
US5869315A (en) | 1995-12-18 | 1999-02-09 | Basf Aktiengesellschaft | Modified interleukin-1β converting enzyme with increased stability |
HU230160B1 (hu) | 1996-02-09 | 2015-09-28 | Swedish Orphan Biovitrum Ab (Publ) | Interleukin-I inhibitort és kontrollált felszabadulású polimerként hialuronant tartalmazó készítmények |
GB9621859D0 (en) | 1996-10-21 | 1996-12-11 | Xenova Ltd | Cytokine production inhibitors |
AU728760B2 (en) | 1996-11-20 | 2001-01-18 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
US5955480A (en) | 1996-11-20 | 1999-09-21 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
US6054559A (en) | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
DE69729762T2 (de) | 1997-01-29 | 2005-07-14 | Pfizer Inc. | 4-Substituiertes Furan-2-sulfonamid und dessen Verwendung in der Herstellung von Sulfonylharnstoff-Derivate |
WO1998042325A2 (en) | 1997-03-21 | 1998-10-01 | Cistron Biotechnology, Inc. | INHIBITION OF THE CLEAVAGE OF PRECURSOR IL-1$g(b) |
EP0979099B1 (en) | 1997-04-10 | 2005-06-15 | Agennix, Inc. | Use of lactoferin in the treatment of allergen induced disorders |
KR100568438B1 (ko) | 1997-04-24 | 2006-04-07 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 염증성 질환의 치료에 유용한 치환된 이미다졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
FR2762514B1 (fr) | 1997-04-29 | 1999-10-22 | Sanofi Sa | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
WO1998056377A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
EP0994858A1 (en) | 1997-06-30 | 2000-04-26 | Ortho-McNeil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
AR016551A1 (es) | 1997-07-30 | 2001-07-25 | Smithkline Beecham Corp | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos |
ES2284214T3 (es) | 1997-08-04 | 2007-11-01 | Millennium Pharmaceuticals, Inc. | Nuevas moleculas de la familia de las proteinas tango-77 y usos de las mismas. |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
US5998469A (en) | 1998-01-16 | 1999-12-07 | Centaur Pharmaceuticals, Inc. | Thioether furan nitrone compounds |
WO1999036426A1 (en) | 1998-01-20 | 1999-07-22 | Warner-Lambert Company | N-[2-(5-BENZYLOXYCARBONYL-AMINO-6-OXO-2-(4-FLUOROPHENYL)-1,6-DIHYDRO-1-PYRIMIDINYL)ACETO- XYL]-L-ASPARTIC ACID ALDEHYDE AS AN IN VIVO INHIBITOR OF INTERLEUKIN-1β CONVERTING ENZYME (ICE) |
IL137037A0 (en) | 1998-01-23 | 2001-06-14 | Immunex Corp | Acpl dna and polypeptides |
ATE296812T1 (de) | 1998-03-09 | 2005-06-15 | Vertex Pharma | 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms |
JP2002506829A (ja) | 1998-03-16 | 2002-03-05 | サイトビア インコーポレイテッド | ジペプチドのアポトーシスインヒビターおよびそれらの使用 |
EP2261232A3 (en) | 1998-03-19 | 2011-04-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
JP2002512776A (ja) | 1998-04-28 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | 免疫原性の低下したモノクローナル抗体 |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
JP2000209980A (ja) * | 1998-11-20 | 2000-08-02 | Oriental Yeast Co Ltd | インタ―ロイキン―1関連疾患モデルノックアウト動物 |
US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US7109003B2 (en) * | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US20070292411A1 (en) * | 2000-11-08 | 2007-12-20 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
EP1396500A4 (en) * | 2001-05-18 | 2005-02-02 | Kirin Brewery | ANTI-TRAIL-R ANTIBODIES |
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
EP1537140B1 (en) * | 2001-11-07 | 2013-01-02 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
EP1506286B1 (en) * | 2002-05-24 | 2014-03-19 | Merck Sharp & Dohme Corp. | Neutralizing human anti-igfr antibody |
EP1542724A4 (en) * | 2002-08-19 | 2005-10-19 | Abgenix Inc | ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF |
NZ593428A (en) * | 2002-09-06 | 2013-01-25 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
WO2004084823A2 (en) * | 2003-03-19 | 2004-10-07 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
EP2484696B1 (en) * | 2006-08-28 | 2017-08-16 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic hLIGHT-specific human monoclonal antibodies |
-
2003
- 2003-09-05 NZ NZ593428A patent/NZ593428A/xx not_active IP Right Cessation
- 2003-09-05 JP JP2004534705A patent/JP4317817B2/ja not_active Expired - Lifetime
- 2003-09-05 NZ NZ605429A patent/NZ605429A/en not_active IP Right Cessation
- 2003-09-05 NZ NZ566539A patent/NZ566539A/en not_active IP Right Cessation
- 2003-09-05 DK DK03752058.2T patent/DK1572946T3/da active
- 2003-09-05 CA CA2497884A patent/CA2497884C/en not_active Expired - Lifetime
- 2003-09-05 AR ARP030103239A patent/AR041173A1/es active IP Right Grant
- 2003-09-05 EA EA201300022A patent/EA033750B1/ru not_active IP Right Cessation
- 2003-09-05 RS YU20050198A patent/RS52889B/sr unknown
- 2003-09-05 MX MXPA05002514A patent/MXPA05002514A/es active IP Right Grant
- 2003-09-05 PL PL377091A patent/PL377091A1/pl unknown
- 2003-09-05 CN CN200910009932.1A patent/CN101628939B/zh not_active Expired - Lifetime
- 2003-09-05 BR BRPI0314038A patent/BRPI0314038B8/pt not_active IP Right Cessation
- 2003-09-05 AU AU2003270370A patent/AU2003270370A1/en not_active Abandoned
- 2003-09-05 TW TW095140332A patent/TWI289668B/zh not_active IP Right Cessation
- 2003-09-05 RS RS20130234A patent/RS20130234A1/sr unknown
- 2003-09-05 US US10/656,769 patent/US7438910B2/en not_active Expired - Lifetime
- 2003-09-05 SI SI200332158T patent/SI1572946T1/sl unknown
- 2003-09-05 TW TW092124638A patent/TWI347951B/zh not_active IP Right Cessation
- 2003-09-05 SG SG2008082836A patent/SG196688A1/en unknown
- 2003-09-05 KR KR1020057003934A patent/KR101317045B1/ko active IP Right Grant
- 2003-09-05 CA CA2824167A patent/CA2824167C/en not_active Expired - Lifetime
- 2003-09-05 TW TW097108173A patent/TWI367102B/zh not_active IP Right Cessation
- 2003-09-05 EA EA200500441A patent/EA018072B1/ru not_active IP Right Cessation
- 2003-09-05 ME MEP-325/08A patent/MEP32508A/xx unknown
- 2003-09-05 EP EP03752058A patent/EP1572946B1/en not_active Expired - Lifetime
- 2003-09-05 EP EP15190744.1A patent/EP3020414B1/en not_active Expired - Lifetime
- 2003-09-05 ES ES10010884.4T patent/ES2565189T3/es not_active Expired - Lifetime
- 2003-09-05 NZ NZ538569A patent/NZ538569A/en not_active IP Right Cessation
- 2003-09-05 CN CN201410210414.7A patent/CN104178491B/zh not_active Expired - Lifetime
- 2003-09-05 ES ES03752058T patent/ES2384379T3/es not_active Expired - Lifetime
- 2003-09-05 AT AT03752058T patent/ATE549033T1/de active
- 2003-09-05 CN CNB038248468A patent/CN100471871C/zh not_active Expired - Lifetime
- 2003-09-05 DK DK10003365.3T patent/DK2213685T3/da active
- 2003-09-05 ME MEP-2008-325A patent/ME00204B/me unknown
- 2003-09-05 PT PT03752058T patent/PT1572946E/pt unknown
- 2003-09-05 EP EP10003365.3A patent/EP2213685B1/en not_active Expired - Lifetime
- 2003-09-05 KR KR1020117024516A patent/KR101311141B1/ko active IP Right Grant
- 2003-09-05 WO PCT/US2003/027978 patent/WO2004022718A2/en active Application Filing
- 2003-09-05 SG SG2013096847A patent/SG2013096847A1/en unknown
- 2003-09-05 ES ES10003365.3T patent/ES2449578T3/es not_active Expired - Lifetime
- 2003-09-05 EP EP10010884.4A patent/EP2277543B1/en not_active Expired - Lifetime
- 2003-09-05 NZ NZ581996A patent/NZ581996A/en not_active IP Right Cessation
-
2005
- 2005-02-23 IL IL167073A patent/IL167073A/en active IP Right Grant
- 2005-02-25 NO NO20051048A patent/NO337245B1/no not_active IP Right Cessation
- 2005-03-02 ZA ZA2005/01792A patent/ZA200501792B/en unknown
-
2006
- 2006-03-14 HK HK06103195.1A patent/HK1084688A1/xx not_active IP Right Cessation
-
2008
- 2008-07-31 JP JP2008199044A patent/JP2009040781A/ja not_active Withdrawn
- 2008-08-22 AU AU2008207483A patent/AU2008207483B2/en not_active Expired
- 2008-09-15 US US12/210,313 patent/US8236559B2/en not_active Expired - Lifetime
-
2009
- 2009-03-09 JP JP2009055682A patent/JP5435986B2/ja not_active Expired - Lifetime
- 2009-04-27 IL IL198420A patent/IL198420A/en active IP Right Grant
-
2011
- 2011-07-24 IL IL214262A patent/IL214262A0/en unknown
- 2011-07-24 IL IL214263A patent/IL214263A/en active IP Right Grant
- 2011-07-26 HK HK11107768.2A patent/HK1153649A1/zh not_active IP Right Cessation
-
2012
- 2012-04-18 US US13/450,126 patent/US8518407B2/en not_active Expired - Lifetime
- 2012-06-01 PH PH12012501089A patent/PH12012501089A1/en unknown
- 2012-06-12 CY CY20121100529T patent/CY1112858T1/el unknown
- 2012-10-03 JP JP2012221289A patent/JP2013063973A/ja not_active Withdrawn
-
2013
- 2013-08-07 US US13/961,537 patent/US8710203B2/en not_active Expired - Lifetime
-
2014
- 2014-03-05 US US14/198,131 patent/US9534053B2/en active Active
-
2015
- 2015-06-02 HK HK15105226.8A patent/HK1204654A1/xx unknown
- 2015-08-28 NO NO20151100A patent/NO339345B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE549033T1 (de) | Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper | |
CY2016035I1 (el) | Θεραπευτικη χρηση αντισωματων anti-cs1 | |
CY2012019I1 (el) | Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20 | |
DE602004026768D1 (de) | Therapeutische anti-igfr1-antikörper-kombinationen | |
IS7499A (is) | Mennsk mótefni gegn beta-amýloíðpeptíðum | |
IS8266A (is) | Breytt mennsk IGF-1R mótefni | |
NO20044347L (no) | Anti-alfavbeta6-antistoff | |
IL200604A0 (en) | Human monoclonal antibodies against cd30 | |
DK1501856T3 (da) | Anti-HER2 antistofvarianter | |
DK1578397T3 (da) | Humane monoklonale antistoffer mod CD25 | |
IS7668A (is) | Manngerð mótefni gegn 4-1BB í mönnum | |
IS6779A (is) | Mannlíkt mótefni gegn LT-beta-R | |
EP1572131A4 (en) | ANTIBODY THERAPY | |
DE60222658D1 (de) | Monoklonaler anti-cd-40-antikörper | |
IL165256A0 (en) | Neutralizing human anti-igfr antibody | |
NO20050689L (no) | Terapeutisk anvendelse | |
DE112004002660D2 (de) | Humaner monoklonaler Antikörper mit fettsenkender Wirkung | |
FI20011055A (fi) | Heveiiniä sitovat monoklonaaliset vasta-aineet | |
AR028262A1 (es) | Anticuerpos especificos de fap-alfa humanos | |
GB0325391D0 (en) | Human monoclonal antibodies | |
DE10194099D2 (de) | Monoklonale Antikörper gegen Humanes Cathepsin W | |
DK1494693T3 (da) | Cripto-specifikke antistoffer | |
ATE506966T1 (de) | Humanisierte super-antikörper | |
SE0203826D0 (sv) | Therapeutic agents | |
SE0200450D0 (sv) | Therapeutic agents |